ID
30264
Beskrivning
https://clinicaltrials.gov/show/NCT00989664 Independent Response Evaluation, Oncologist's Assessment Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Länk
https://clinicaltrials.gov/show/NCT00989664
Nyckelord
Versioner (1)
- 2018-05-25 2018-05-25 -
Rättsinnehavare
GlaxoSmithKline (GSK)
Uppladdad den
25 maj 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664
Independent Response Evaluation, Oncologist's and Joint Assessment
Similar models
Independent Response Evaluation, Oncologist's and Joint Assessment
C0259990 (UMLS CUI-2)
C0220825 (UMLS CUI-3)
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0376298 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C0259990 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C0376298 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C0259990 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C0031831 (UMLS CUI [1,2])
C1514693 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])